Does the MCA accept that paroxetine is associated with a characteristic withdrawal syndrome?
There is no regulatory requirement for MCA to denote whether the collection of symptoms commonly seen on withdrawal of paroxetine or other SSRIs constitute a characteristic withdrawal syndrome. There are some symptoms which occur more commonly on withdrawal of paroxetine and other SSRIs than others. 5. Does the MCA believe that the majority of Yellow Cards for paroxetine report something other than a withdrawal syndrome ? The majority of reporters use the term withdrawal reactions . 6. In the MCA paper, WHAT IS A SERIOUS REACTION, examples of serious reactions include withdrawal syndrome . Is there any difference between this withdrawal syndrome and the withdrawal syndrome seen with paroxetine? This paper is a guide for reporters as to the reactions which we would consider fall within the regulatory criteria for a serious reaction that is they are potentially fatal, life threatening, disabling, incapacitating, result in or prolong hospitalisation or are otherwise medically significant
Related Questions
- Is there a central nervous withdrawal syndrome associated with discontinuing long-term treatment with propranolol?
- What are some of the symptoms associated with poor indoor air quality or sick building syndrome (SBS)?
- Does the MCA accept that paroxetine is associated with a characteristic withdrawal syndrome?
